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Beige adipocytes emerge postnatally within the white
adipose tissue in response to certain environmental cues,
such as chronic cold exposure. Because of its highly
recruitable nature and relevance to adult humans, beige
adipocytes have gained much attention as an attractive
cellular target for antiobesity therapy. However, molec-
ular circuits that preferentially promote beige adipocyte
biogenesis remain poorly understood. We report that a
combination of mild cold exposure at 17°C and capsi-
noids, a nonpungent analog of capsaicin, synergistically
and preferentially promotes beige adipocyte biogenesis
and ameliorates diet-induced obesity. Gain- and loss-of-
function studies show that the combination of capsinoids
and cold exposure synergistically promotes beige adipo-
cyte development through the b2-adrenoceptor signaling
pathway. This synergistic effect on beige adipocyte bio-
genesis occurs through an increased half-life of PRDM16,
a dominant transcriptional regulator of brown/beige ad-
ipocyte development. We document a previously unap-
preciated molecular circuit that controls beige adipocyte
biogenesis and suggest a plausible approach to increase
whole-body energy expenditure by combining dietary
components and environmental cues.
Obesity develops from a chronic imbalance in energy
homeostasis between energy intake and energy expen-
diture. Currently, all the available antiobesity medica-
tions act by limiting energy intake through suppression of
appetite or inhibition of intestinal lipid absorption; however,
long-term use of such medications often is associated with
adverse effects, such as depression and steatorrhoea (1).
Over the past few years, a growing body of evidence from
studies on rodent models and adult humans has indi-
cated that activating thermogenesis in brown adipose tis-
sue (BAT) is a plausible alternative approach to modulate
whole-body energy balance (2).
Brown adipocytes dissipate chemical energy and pro-
duce heat through the BAT-specific mitochondrial protein
uncoupling protein 1 (UCP1). The thermogenic capacity of
UCP1 to uncouple cellular respiration from ATP synthesis
is highly regulated by the activation of b-adrenoreceptors
(b-ARs) through the sympathetic nervous system. At a
molecular level, catecholamines released from sympa-
thetic nerve terminals bind to b-ARs in response to cold
exposure, leading to the production of free fatty acids by
lipolysis. The produced free fatty acids are a critical switch
for the proton uncoupling activity of UCP1 (3). Extensive
efforts have been made to pharmacologically activate BAT
thermogenesis by using synthetic b-AR agonists. Re-
cently, a selective b3-AR agonist, mirabegron, has been
demonstrated to powerfully activate BAT metabolic activ-
ity, as assessed by 18F-fluoro-2-deoxy-D-glucose positron
emission tomography/computed tomography scans, which
leads to an increased resting metabolic rate in healthy adult
humans who possess detectable BAT depots (4). On the
other hand, the efficacy of the b3-AR agonists was mar-
ginal or absent in the obese population (5,6). Furthermore,
impaired expression and functional activity of b3-AR are
reported in obese animals and humans. For example, a
variant allele of the human b3-AR gene (64 Trp/Arg) is
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associated with reduced b3-AR signaling (7,8) and increased
BMI and adiposity (9,10). Hence, understanding the regu-
latory circuits that enhance the b-AR signaling pathway
within adipose tissues is important such that clinically sig-
nificant efficacy can be achieved even in obese subjects.
Rodents and humans possess two distinct forms of
UCP1-positive thermogenic adipocytes: classical brown
adipocytes and beige adipocytes (also referred to as brite
adipocytes). Whereas classical brown adipocytes and beige
adipocytes share many functional characteristics (i.e.,
thermogenesis), they are distinct cell types at develop-
mental, anatomical, and molecular levels. Classical brown
adipocytes are prenatally derived from a subset of dermo-
myotome, whereas beige/brite adipocytes postnatally
emerge within white adipose tissue (WAT) in response
to certain environmental cues, such as chronic cold
exposure, exercise, and long-term treatment with peroxi-
some proliferator–activated receptor-g (PPARg) agonists
(11–13). The environmental cue–induced beige adipocyte
biogenesis in WAT often is referred to as WAT browning.
Of note, molecular signatures of adult human BAT have
been shown to resemble mouse beige adipocytes (12,14–17).
We recently found that clonally derived adult human
brown adipocytes possess beige-like characteristics based
on unbiased RNA sequencing analyses (17). Furthermore,
chronic cold exposure for up to 6 weeks recruits new active
BAT depots in adult humans who did not possess appre-
ciable levels of BAT depots before cold exposure (18–20).
An emergence of the newly recruited BAT has been asso-
ciated with an increase in cold-stimulated energy expendi-
ture or with improved postprandial insulin sensitivity. The
findings from these studies suggest that adult human BAT
largely comprises the recruitable form of thermogenic ad-
ipocytes, that is, beige adipocytes. Hence, understanding
molecular circuits that preferentially promote beige adipo-
cyte biogenesis may provide a new opportunity for anti-
obesity therapies for obese or older individuals who do not
possess active BAT depots.
Capsinoids are capsaicin analogs found in a nonpungent
type of chili pepper, CH-19 Sweet (21,22). Although cap-
sinoids differ from capsaicin only in their chemical struc-
ture at an ester bond in the center linkage, they possess
substantially less pungency than capsaicin by at least
1,000-fold. Dietary supplementation with capsinoids leads
to an increase in energy expenditure and reduced body
weight gain in animal models as well as in adult humans
(23,24). For example, Yoneshiro et al. (20) showed that
prolonged dietary supplementation with capsinoids for
6 weeks increased cold-induced thermogenesis in adult hu-
mans. Given the relevance of beige adipocytes in adult
humans, it is hypothesized that long-term capsinoids treat-
ment promotes beige adipocyte biogenesis. However, the
underlying mechanisms remain poorly understood.
We report that dietary supplementation of capsinoids
in a mild cold environment (17°C) powerfully and prefer-
entially promotes beige adipocyte biogenesis in rodent
models. This WAT browning effect by capsinoids was
well associated with an increase in whole-body energy
expenditure. Gain- and loss-of-function studies showed
that beige adipocyte biogenesis by capsinoids is largely
mediated through an activation of the b2-AR signaling
pathway. Of note, we found that an activation of the
b2-AR signaling pathway enhanced the protein half-life of
PRDM16, a dominant transcriptional regulator of brown
and beige adipocyte development. These results illuminate
a molecular circuit that preferentially promotes beige
adipocyte development in vivo. This study also suggests a
plausible approach to increasing whole-body energy expen-
diture through dietary components.
RESEARCH DESIGN AND METHODS
Animals
Male C57BL/6J mice were purchased from Charles River
at 7 weeks of age. Triple knockout mice of the b1-, b2-,
and b3-ARs (b-less mice) were a gift from B.B. Lowell of
Harvard Medical School. Mice were kept at 176 1°C (17°C)
or 25 6 1°C (25°C) in a controlled light environment
(12-h cycle). The temperature was precisely controlled by
an animal environmental control system (LP-30CCFL-
8CTAR; NKsystem).
After a 1-week acclimation at 17°C or 25°C on a regular
diet, the mice were randomly assigned to two groups. One
group (n = 6) was allowed ad libitum access to a high-fat
diet (HFD), and the other group (n = 6) received an HFD
supplemented with 0.3% (weight for weight) capsinoids,
which contained capsiate (62.7%), dihydrocapsiate (32.2%),
and nordihydrocapsiate (5.5%) (Yoyu-Lab) for 8 weeks.
Nutritional content of the HFD containing capsinoids is
provided in Supplementary Table 1. The experiments in
b-less mice were performed for 4 weeks.
For the pharmacological experiments using b-AR an-
tagonists, 9-week-old male C57BL/6J mice were kept at 17°C
and fed an HFD or HFD supplemented with 0.3% capsinoids.
Mice were injected subcutaneously with a b2-AR antagonist
(ICI 118,551; Tocris) at a dose of 2 mg/kg/day or a b3-AR
antagonist (SR59230A; Sigma-Aldrich) at a dose of
1 mg/kg/day for 4 weeks. For the experiments using
b-AR agonists, 8-week-old male C57BL/6J mice were in-
jected intraperitoneally with a b2-AR agonist (formoterol;
Santa Cruz Biotechnology) at a dose of 1 mg/kg or a b3-AR
agonist (CL316243; Sigma-Aldrich) at a dose of 1 mg/kg for
1 week. The dose of each compound was based on the
previous studies that used the b3-AR agonist for the induc-
tion of beige adipocyte development in mice (15). All animal
protocols were approved by the Animal Committee of
Ajinomoto Co., Inc., or by the Institutional Animal Care and
Use Committee at the University of California, San Francisco.
Metabolic Parameters
Whole-body energy expenditure of mice was assessed with
a metabolic chamber (ARCO2000-RAT/ANI System; Arco)
as described previously (23). Mice were injected intraper-
itoneally with vehicle (saline) or CL316243 at a dose of
0.01 mg/kg during the measurements. The respiratory
diabetes.diabetesjournals.org Ohyama and Associates 1411
quotient (VCO2/VO2) was calculated based on Weir (25).
Spontaneous activity of the mice was simultaneously mea-
sured with an activity sensor (NS-AS01; Neuroscience). All
measurements were performed at 4.5-min intervals.
For the glucose tolerance test, mice were injected with
glucose 1 g/kg i.p. after a 6-h fast. An insulin tolerance
test was performed by injecting insulin 0.75 units/kg after
an overnight fast. Blood glucose levels were measured
with blood glucose test strips (Arkary) postinjection at 15,
30, 60, and 120 min. Fasting plasma glucose levels were
determined with FUJI DRI-CHEM (Fujifilm). Plasma insulin
levels were measured with a commercially available ELISA
(Morinaga). Plasma triglyceride (TG) levels were measured
with a Wako TG test kit. Total liver lipids were extracted with
a chloroform:methanol mixture (2:1 volume for volume) as
described by Folch et al. (26). The liver TG concentration in
the lipid extracts was also measured with the Wako TG test.
Cell Culture
Stromal vascular (SV) fraction was isolated as described by
Ohno et al. (27). Adipocyte differentiation was induced in
advanced DMEM/F12 medium (D-glucose 25 mmol/L) con-
taining 10% FBS, 0.5 mmol/L isobutylmethylxanthine,
125 nmol/L indomethacin, 5 mmol/L dexamethasone,
850 nmol/L insulin, and 1 nmol/L triiodothyronine.
Two days later, the cells were placed in maintenance me-
dium containing 10% FBS, 850 nmol/L insulin, and 1
nmol/L triiodothyronine.
For PRDM16 knockdown experiments in cultured adi-
pocytes, we infected inguinal WAT–derived SV cells with
adenoviral vectors expressing short hairpin RNA targeting
PRDM16 (sh-PRDM16) or a scramble control (sh-scr) (27).
The cells were allowed to differentiate for 7 days into ma-
ture adipocytes in the absence or presence of 1 mmol/L of
the b2-AR agonist formoterol.
Gene Expression Analysis
Total RNA was isolated using RiboZol (AMRESCO) according
to the manufacturer’s protocol. Reverse transcription reactions
were performed with an iScript cDNA Synthesis Kit (Bio-Rad).
The primer sequences used in the amplification are shown in
Supplementary Table 2. Quantitative RT-PCR (qRT-PCR) was
performed with iTaq Fast SYBR Green Supermix (Bio-Rad)
using an ABI ViiA 7 PCR machine (Life Technologies). Relative
mRNA expression was determined by the DD-Ct method,
using TATA-binding protein (TBP) as an internal control.
Western Blotting
Total tissue lysates from BAT and WAT were prepared
in radioimmunoprecipitation assay buffer containing
25 mmol/L Tris-HCl (pH 7.6), 1% NP-40, 0.5% sodium
deoxycholate, 0.1% SDS, and 150 mmol/L NaCl supple-
mented with 1% protease inhibitor (Nacalai Tesque). The
protein content was determined by using a Bradford protein
assay (Bio-Rad). Proteins were separated by using 7.5% or
10% SDS-PAGE and transferred to nitrocellulose membranes
(Bio-Rad). The membranes were subsequently probed with
antibodies for UCP1 (ab10983 1:2,000 dilution; Abcam) or
Prdm16 (ab106410 1:2,000 dilution; Abcam). A b-actin
antibody (ab8228 1:5,000 dilution; Abcam) was used as a
loading control. Proteins were detected using horseradish
peroxidase (HRP)–conjugated IgG secondary antibody (goat
anti-rabbit IgG-HRP, 4010-05 1:10,000 dilution; Southern
Biotech) and Chemi-Lumi One Super (Nacalai Tesque).
Immunohistochemistry
Tissues were fixed overnight at 4°C in 4% paraformalde-
hyde, washed three times in PBS, infiltrated with 12.5–30%
sucrose followed by optimal cutting temperature com-
pound, and frozen in liquid nitrogen. Using a Leica
CM3050 S cryostat (Leica Microsystems), 8–12-mm-thick
sections were cut, fixed, and permeabilized in 10 mmol/L
citric acid (pH 6.0) for 20 min at 121°C and then incubated
for 20 min with 2% BSA in PBS. They were incubated for
1 h with an antibody for UCP1 (ab10983 1:2,000 dilution)
followed by incubation with secondary HRP-conjugated an-
tibodies (goat anti-rabbit IgG-HRP, 4010-05 1:200 dilution)
and detected with the AEC Chromogen Kit (Sigma).
Protein Stability Assay
Inguinal WAT–derived SV cells were differentiated into
mature adipocytes in the presence or absence of 1 mmol/L
formoterol. Subsequently, the differentiated adipocytes were
incubated in medium containing cycloheximide (20 mg/mL)
for 1, 8, 16, and 24 h. Cell lysates were subjected to Western
blotting to quantify the endogenous PRDM16 protein levels.
b-Actin was used as a loading control. ImageJ software was
used to quantify the signal intensity.
Oxygen Consumption Assays
Mice were anesthetized and transcardially perfused with
Krebs-Ringer bicarbonate HEPES buffer (KRBH) containing
120 mmol/L NaCl, 4 mmol/L KH2PO4, 1 mmol/L MgSO4,
0.75 mmol/L CaCl2, 10 mmol/L NaHCO3, and 30 mmol/L
HEPES (pH 7.4). Adipose depots were carefully dissected and
minced in KRBH supplemented with 0.45 mg/mL D-glucose,
10 mg/mL fatty acid–free BSA, and 1 mg/mL collagenase II
(Sigma). After 1 h of incubation at 37°C, adipose tissues were
filtered through a 200-mm nylon mesh and centrifuged at
200g for 1 min at ambient temperature. The oxygen consump-
tion rate (OCR) of the isolated adipocytes (4–6 3 105 cells
from inguinal WAT) was measured with a Clark-type oxygen
electrode at 37°C in buffer containing KRBH supplemented
with 0.486 mg/mL D-glucose and 40 mg/mL fatty acid–free
BSA in a total volume of 2 mL. Saline or norepinephrine
(100 nmol/L) was added to assess thermogenic response to
cAMP stimuli. OCR was measured every 0.5 s up to 10 min.
Statistical Analysis
Statistical analysis was performed with JMP version 10.0
software (SAS Institute, Inc.). Repeated-measures ANOVA
was applied to compare the time courses. Statistical sig-
nificance was determined with the unpaired two-tailed
Student t test for single- and two-way ANOVAs followed
by Bonferroni posttests for multiple variables. Values are
shown as the mean 6 SEM unless otherwise stated. P ,
0.05 was considered significant.
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RESULTS
A Synergistic Antiobesity Effect by Capsinoids and
Mild Cold Exposure
We first examined whether the effect of capsinoids on
whole-body energy metabolism is influenced by temper-
ature. To this end, C57BL/6J male mice were fed an HFD
containing capsinoids at a concentration of 0.3% or
vehicle under ambient temperature (25°C) and mild cold
conditions (17°C) for 8 weeks. Consistent with previous
studies (23), mice gained modest, but significantly less
body weight on a capsinoids-supplemented diet compared
with mice on a control diet when kept at ambient tem-
perature. The antiobesity effect by capsinoids was signif-
icantly enhanced under mild cold at 17°C (Fig. 1A). This
Figure 1—Capsinoids (CSNs) andmild cold exposure synergistically suppressed body weight gain and increased whole-body energy expenditure
on an HFD. A: Changes in body weight of C57BL/6J male mice (n = 6). Mice were fed an HFD supplemented with 0.3% CSNs (+) or vehicle
(CSNs [2]) for 8 weeks under ambient temperature (RT) or 17°C. Data are mean 6 SEM. *P < 0.05, ***P < 0.001. B: Changes in body weight of
C57BL/6J mice kept under thermoneutral conditions (30°C) (n = 6). C57BL/6J male mice were fed an HFD supplemented with 0.3% CSNs (+) or
vehicle (CSNs [2]) for 8 weeks. C: Whole-body OCR (mL/min) per mouse was measured in C57BL/6J male mice fed an HFD supplemented with
0.3% CSNs (+) or vehicle (CSNs [2]) at RT or at 17°C (n = 6). To stimulate BAT thermogenesis, mice were injected with vehicle (saline) or the
b3-AR agonist (CL316243) at a dose of 0.01 mg/kg body weight. OCRwasmonitored for 3 h after the injection. Quantification of changes in VO2 in
response to CL316243 is also shown (right). These changes were calculated by subtracting the VO2 of vehicle-treated mice from the VO2 of b3-AR
agonist–treated mice. *P< 0.05. D: Fasting blood glucose levels and fasting insulin levels in mice in panel A. Mice were fasted for 3 h before blood
collection. *P< 0.05, **P< 0.01, ***P< 0.001. E: Total lipid content and TG content were measured in the liver of mice in panel A. *P< 0.05, **P<
0.01, ***P < 0.001. N.S., not significant.
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Figure 2—Capsinoids (CSNs) and mild cold exposure synergistically promote beige adipocyte biogenesis in inguinal WAT. A: Relative
mRNA expression levels of Ucp1, Pgc1a, Cidea, and Cox8b were measured by qRT-PCR in the inguinal WAT and the interscapular BAT of
mice kept under ambient temperature (RT) or 17°C (n = 6). Mice were fed an HFD supplemented with 0.3% CSNs (+) or vehicle (CSNs [2])
for 8 weeks. Data are mean 6 SEM. *P < 0.05. B: UCP1 protein levels were analyzed by Western blotting in the inguinal WAT and the
interscapular BAT from mice in panel A. b-Actin was used as a loading control. C: Immunohistochemistry of UCP1 in the inguinal WAT and
the interscapular BAT from mice in panel A. Scale bar = 100 mm. D: Cellular respiration was measured in isolated adipocytes from the
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antiobesity effect by the combination of capsinoids and
mild cold exposure was synergistic because capsinoids sup-
plementation under 17°C led to a 31% suppression of diet-
induced body weight gain compared with control mice,
whereas capsinoids or mild cold exposure alone reduced
body weight gain by 14% and 12%, respectively. The syn-
ergy is statistically significant according to the analysis by
interaction plot (P = 0.03). This synergistic antiobesity
effect was independent of changes in energy intake and
behavior because no major difference was observed in
food intake and locomotor activity between the vehicle-
and capsinoids-treated groups both at ambient and cold
temperature (Supplementary Fig. 1A and B). We also found
that the antiobesity effect by capsinoids was completely
blunted under thermoneutral conditions at 30°C (Fig.
1B). These data indicate that dietary supplementation of
capsinoids promotes cold-induced thermogenesis in vivo.
We next measured changes in whole-body OCR of mice
treated with vehicle and capsinoids in response to the b3-
AR agonist CL316243 to mimic cold-induced activation of
b3-AR signaling. As shown in Fig. 1C, CL316243 signifi-
cantly increased the whole-body OCR, representing BAT-
mediated thermogenesis (28). The b3-AR agonist–induced
whole-body OCR was increased in mice treated with cap-
sinoids compared with vehicle-treated mice under 17°C
(Fig. 1C and Supplementary Fig. 2).
To further examine metabolic consequences of cap-
sinoids supplementation and mild cold exposure, we
assessed systemic glucose homeostasis and lipid metab-
olism by examining fasting glucose levels, insulin levels,
and hepatic lipid contents. Consistent with the changes
in body weight, we found that fasting plasma concen-
trations of glucose and insulin were significantly lower in
mice treated with capsinoids under 17°C than in vehicle-
treated mice and in mice kept under ambient tempera-
ture (Fig. 1D). In addition, glucose tolerance and insulin
sensitivity, as assessed by glucose and insulin tolerance
tests, respectively, were significantly improved in mice
treated with capsinoids under 17°C (Supplementary Fig.
3A and B). We also found that hepatic steatosis was
improved by the combination of capsinoids and mild
cold because total lipid and TG content in the liver was
significantly reduced in mice treated with capsinoids un-
der 17°C (Fig. 1E).
Capsinoids and Mild Cold Exposure Synergistically
Promote Beige Adipocyte Biogenesis in Inguinal WAT
On the basis of the aforementioned observation that
capsinoids supplementation under mild cold temperature
at 17°C synergistically increases energy expenditure, we
hypothesized that this increase was through an activa-
tion of the thermogenic program in the interscapular BAT
depots and/or through recruitment of new beige adipo-
cytes in the subcutaneous WAT depots. To this end, we
first measured mRNA expression of the BAT-selective
genes and beige adipocyte–selective genes in the inguinal
WAT and in the interscapular BAT depots by qRT-PCR.
Expression of the BAT-selective genes, such as Ucp1,
Pgc1a, and Cidea, and beige adipocyte–selective genes,
such as Cd137 and Tmem26, was significantly higher in
the inguinal WAT of mice treated with capsinoids under
17°C than in vehicle-treated mice and mice kept under
ambient temperature (Fig. 2A and Supplementary Fig.
4A, left panel). No significant change was observed in
the expression of a general adipogenic marker, adiponec-
tin (Adipoq) (Supplementary Fig. 5). We did not observe
statistically significant changes in mRNA expression of
the thermogenic genes and beige adipocyte–selective
markers in the interscapular BAT depots by capsinoids
treatment, although the UCP1 mRNA levels were ;100-
fold higher in the BAT than in the inguinal WAT (Fig. 2A
and Supplementary Fig. 4A, right panel, and B).
Consistent with the increase in Ucp1 mRNA expression,
we also observed a striking increase in UCP1 protein ex-
pression in the inguinal WAT of mice treated with capsi-
noids under 17°C (Fig. 2B, left panel). In contrast, we did
not observe major changes in UCP1 protein expression in
the interscapular BAT by capsinoids and mild cold exposure
(Fig. 2B, right panel), although UCP1 expression in BAT
was 50-fold higher than in inguinal WAT when normalized
to b-actin (Fig. 2B and Supplementary Fig. 6). This signif-
icant increase in UCP1 expression in the inguinal WAT was
tightly associated with an increase in the number of UCP1-
positive beige adipocytes containing multilocular lipid
droplets (Fig. 2C, left panels). We did not observe major
changes in UCP1 density in the interscapular BAT depots,
although adipocyte size appeared smaller in the BAT from
mice treated with capsinoids (Fig. 2C, right panels).
To examine thermogenic function of the newly recruited
beige adipocytes, we measured cellular respiration of adi-
pocytes isolated from the inguinal WAT of mice treated with
capsinoids under 17°C or ambient temperature. As shown in
Fig. 2D, adipocytes from mice treated with capsinoids under
17°C exhibited significantly higher cellular respiration in re-
sponse to norepinephrine stimulation, whereas no major
change was seen in adipocytes from vehicle-treated mice
and from mice under ambient temperature. Together, these
results suggest that a combination of capsinoids supplemen-
tation and mild cold exposure synergistically and preferen-
tially promotes beige adipocyte biogenesis in vivo.
Although capsinoids are hydrolytically unstable under
aqueous conditions and quickly degraded in the gastro-
intestinal tract (29), we tested the possibility that
capsinoids in the circulation may directly promote beige
inguinal WAT of mice in panel A. To stimulate thermogenesis, the cells were treated with saline or norepinephrine (NE) at a dose of 1 mmol/L
at the 0 time point (indicated by arrowheads). N.S., not significant.
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Figure 3—The b-AR pathway is required for the capsinoids (CSNs)-induced antiobesity effect and beige adipocyte biogenesis. A: Changes
in body weight of WT and b-less mice fed an HFD supplemented with 0.3% CSNs (+) or vehicle (CSNs [2]) for 4 weeks (n = 6–8). Mice were
kept under 17°C throughout the experiments. Data are mean6 SEM. *P< 0.05. B: Relative mRNA expression levels of Ucp1, Pgc1a, Dio2,
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adipocyte biogenesis by using the plasma from mice fed
capsinoids. The plasma samples were isolated from the
mice that exhibited higher levels of UCP1 and other beige
adipocyte–selective gene expression by capsinoids treatment.
As shown in Supplementary Fig. 7, the plasma from mice fed
capsinoids did not affect the expression of thermogenic
genes in inguinal WAT–derived primary adipocytes.
The b-AR Pathway Is Required for the
Capsinoids-Induced Antiobesity Effect and Beige
Adipocyte Biogenesis
We have previously shown that capsinoids activate the
sympathetic nervous system through the gastrointestinal
transient receptor potential vanilloid type 1 (TRPV1)
channel (30). Because b-ARs play a dominant role in the
control of brown and beige adipocyte biogenesis, we hypo-
thesized that capsinoids act through the b-adrenergic
signaling pathway to promote beige adipocyte develop-
ment. To test this hypothesis, we treated b-less mice
(31) that lack all three forms of b-ARs (i.e., b1, b2, and
b3) with capsinoids under 17°C. Because b-less mice were
bred in a mixed genetic background (FVB/C57BL/6J/DBA/
2/129SvJ) (31), we used the corresponding age-matched
wild-type (WT) mice (6 weeks old) in a mixed genetic
background as a control group. Hereafter, we performed
all metabolic studies under 17°C. Consistent with the re-
sults in the C57BL/6J strain, capsinoids treatment for 4
weeks significantly (although modestly) suppressed HFD-
induced body weight gain in WT mice (Fig. 3A, left panel).
In contrast, the suppression in body weight gain by cap-
sinoids treatment was completely abolished in b-less mice
(Fig. 3A, right panel). Expression of BAT-selective genes,
such as Ucp1, Pgc1a, and Dio2, was significantly higher in
the inguinal WAT of WT mice treated with capsinoids
under 17°C, whereas this induction was largely impaired
in b-less mice (Fig. 3B, top panel). Consistent with the
previous study (31), the basal level of Ucp1 expression was
significantly lower in the interscapular BAT of b-less mice
than in WT mice. However, capsinoids treatment did not
alter the BAT-selective gene expression in the interscapular
BAT of WT and b-less mice (Fig. 3B, bottom panel). Sim-
ilarly, capsinoids treatment increased UCP1 protein ex-
pression in the inguinal WAT of WT mice but not in
that of b-less mice (Fig. 3C). These results suggest that
the b-adrenergic pathway is required for capsinoids-
induced beige adipocyte biogenesis.
b2-AR Mediates Capsinoids-Induced Beige Adipocyte
Biogenesis
Because three types of b-ARs (b1, b2, and b3) are expressed
in WAT, we next asked which form of the b-ARs mediates
the biological effect of capsinoids on the browning of WAT
in vivo. We found that expression of b2-AR was significantly
higher in the inguinal WAT of mice treated with capsinoids,
whereas no significant difference was observed in the ex-
pression of b1-AR and b3-AR (Fig. 4A). Hence, we hypoth-
esized that capsinoids promote beige adipocyte biogenesis
through the b2-AR pathway. To this end, we examined the
requirement of b2-AR signaling on the WAT browning by
using a specific b2-AR antagonist (ICI 118,551). As shown in
Fig. 4B (left panel), mice cotreated with capsinoids and the
b2-AR antagonist ICI 118,551 at a dose of 2 mg/kg/day
nearly completely abolished the antiobesity effect of capsi-
noids in mice, even under 17°C. Expression of the BAT-
selective genes, such as Ucp1, Cidea, and Dio2, in the inguinal
WAT was significantly increased by the capsinoids treat-
ment under 17°C; however, such induction was completely
blunted when the b2-AR antagonist was coadministered
(Fig. 4C). Consistent with the changes in gene expression
levels, cotreatment with the b2-AR antagonist blocked
the increase in UCP1 protein expression by capsinoids
(Fig. 4D). Of note, we found that the b3-AR antagonist
(SR59230A) did not block the increase in UCP1 protein
and mRNA expression by capsinoids, indicating that a se-
lective requirement of b2-AR for the capsinoids-induced
beige adipocyte biogenesis (Fig. 4B, right panel, and D).
We next tested whether activation of the b2-AR path-
way is sufficient to promote beige adipocyte biogene-
sis in vivo. Mice were treated with the b2-AR agonist
formoterol or the b3-AR agonist CL316243 at a dose
of 1 mg/kg for 1 week. Formoterol is known to selec-
tively bind and activate b2-AR compared with b3-AR by
645.7-fold (32). As shown in Fig. 4E, the b2-AR agonist
significantly increased mRNA expression of the BAT-
selective genes, such as Ucp1, Cidea, and Dio2, in the
inguinal WAT without affecting mRNA expression of
b-ARs. Additionally, other b2-AR agonists (selectivity
to b2-AR compared with b3-AR: procaterol 1,318.36-
fold, salmeterol 851.1-fold) also recruited browning
(Supplementary Fig. 8). Formoterol powerfully increased
UCP1 protein expression (Fig. 4F) as well as the number
of multilocular beige adipocytes in inguinal WAT (Fig.
4G). These data support our hypothesis that the b2-AR
pathway largely mediates the effects of capsinoids in
promoting beige adipocyte biogenesis in vivo.
Capsinoids Stimulate a Stabilization of the PRDM16
Protein Through the b2-AR Pathway
PRDM16 functions as a dominant transcriptional regula-
tor of brown and beige adipocyte development (33–37).
We have previously shown that protein stabilization of
PRDM16 is a crucial event for PPARg agonist–induced beige
adipocyte development (27). We found that capsinoids ro-
bustly increased PRDM16 protein expression in the inguinal
WAT of mice under ambient temperature and 17°C without
and Adipoq were measured by qRT-PCR in the inguinal WAT and the interscapular BAT from mice shown in panel A. *P< 0.05, **P< 0.01.
C: UCP1 protein expression was analyzed by Western blotting in the inguinal WAT and interscapular BAT from mice shown in panel A.
b-Actin was used as a loading control. N.S., not significant.
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Figure 4—b2-AR mediates the capsinoids (CSNs)-induced beige adipocyte biogenesis. A: Relative mRNA expression levels of b1-AR, b2-
AR, and b3-AR were measured by qRT-PCR in the inguinal WAT of mice fed an HFD supplemented with 0.3% CSNs (+) or vehicle
(CSNs [2]) for 8 weeks (n = 6). Mice were kept under 17°C throughout the experiments. Data are mean 6 SEM. *P < 0.05. B: Changes
in body weight of WT mice fed an HFD supplemented with 0.3% CSNs (+) or vehicle (CSNs [2]) for 4 weeks (n = 6). The mice under 17°C
were injected daily with vehicle (saline) or the b2-AR antagonist (ICI 118,551) at a dose of 2 mg/kg/day. C: Relative mRNA expression levels
of Ucp1, Cidea, Dio2, Adipoq, b1-AR, b2-AR, and b3-AR were measured by qRT-PCR in the inguinal WAT of mice in panel B and mice
injected with vehicle (saline) or a b3-AR antagonist (SR59230A) at a dose of 1 mg/kg/day. *P < 0.05, **P < 0.01. D: UCP1 protein
expression was analyzed by Western blotting in the inguinal WAT of mice shown in panel B and mice injected with the b3-AR antagonist
(SR59230A) at a dose of 1 mg/kg/day. b-Actin was used as a loading control. Quantification of the UCP1/b-actin is also shown (right).
Density of UCP1/b-actin was calculated by ImageJ software. Data are mean 6 SEM. *P < 0.05, **P < 0.01. E: Relative mRNA expression
levels of Ucp1, Cidea, Dio2, aP2, b1-AR, b2-AR, and b3-AR were measured by qRT-PCR in the inguinal WAT of mice injected with vehicle
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affecting its mRNA levels (Fig. 5A). Furthermore, the increase
in PRDM16 protein expression by capsinoids was completely
abolished in b-less mice (Fig. 5B) as well as in mice injected
with the b2-AR antagonist ICI 118,551 (Supplementary Fig.
9). These results indicate that capsinoids stimulate PRDM16
protein accumulation through the b2-AR pathway.
To test whether an activation of the b2-AR pathway is
sufficient to increase PRDM16 protein expression, we in-
jected WT mice with the specific b2-AR agonist formoterol
at 1 mg/kg for 1 week. As shown in Fig. 5C, treatment with
the b2-AR agonist led to a robust increase in PRDM16
protein expression in the inguinal WAT. This increase in
PRDM16 protein expression was tightly correlated with
increases in BAT-selective gene expression and the number
of UCP1-positive beige adipocytes (Fig. 4E–G). Furthermore,
we found that the b2-AR agonist increased PRDM16 protein
expression in a cell-autonomous manner because formoterol
treatment in cultured inguinal WAT–derived primary adipo-
cytes increased PRDM16 protein expression without affect-
ing its mRNA expression (Fig. 5D). Consistent with the
animal experiments, the b2-AR agonist–induced PRDM16
protein expression was highly correlated with an increase in
BAT-selective gene expression in vitro (Supplementary Fig.
10). The b3-AR agonist did not increase PRDM16 protein
expression (Fig. 5D), indicating that b3-AR activation may
induce browning of WAT through a distinct mechanism
from the b2-AR agonist.
We next tested whether the accumulation of PRDM16
protein by b2-AR stimulation was due to changes in the
rate of protein degradation. To this end, we measured the
protein half-life of endogenous PRDM16 by cycloheximide
chase experiments in inguinal WAT–derived primary adipo-
cytes. As shown in Fig. 5E, the b2-AR agonist formoterol
powerfully extended the protein half-life of PRDM16 from
5.6 to 23.9 h. Finally, we tested the requirement of PRDM16
for the b2-AR agonist–induced browning effect. To this end,
inguinal WAT–derived primary preadipocytes were infected
with adenoviral vectors expressing sh-PRDM16 or sh-scr in
the presence or absence of formoterol at a dose of 1 mmol/L
throughout adipocyte differentiation. As shown in Fig. 5F
and G, the b2-AR agonist formoterol did not increase UCP1
expression when adipocytes were depleted with PRDM16.
Altogether, these data indicate that capsinoids act through
the b2-AR pathway to stimulate PRDM16 protein stabili-
zation, leading to a powerful activation of the beige adipo-
cyte gene program in inguinal WAT.
DISCUSSION
Capsinoids, including capsiate, dihydrocapsiate, and
nordihydrocapsiate, are unique capsaicin analogs found
abundantly in a nonpungent type of chili pepper, CH-19
Sweet (21,22). The three forms of capsinoids can directly
bind to TRPV1 at a similar binding affinity to capsaicin;
however, the potency of the capsinoids to increase inter-
cellular Ca2+ levels was ;10 times lower than capsaicin
(38). In addition, the chemical structure of capsinoids is
distinct from capsaicin at an ester bond, making capsinoids
hydrolytically unstable in an aqueous environment
such that they are quickly degraded in the gastrointestinal
tract and not detectable in circulation (29). Hence,
capsinoids promote the browning of WAT largely through
CNS-mediated signaling rather than direct action through
the circulation (Supplementary Fig. 5). How do capsinoids
synergistically promote BAT-mediated thermogenesis to-
gether with mild cold exposure in vivo? As illustrated in
Fig. 6, previous studies have shown that capsinoids act on
TRPV1 in the gut, leading to an activation of vagal affer-
ent nerves that project into the ventromedial hypothal-
amus (VMH) (30). Capsinoids also activate several brain
regions, including the VMH, in a TRPV1-dependent fash-
ion (39). Of note, the VMH is known to control BAT-
mediated thermogenesis by stimulating sympathetic
efferent (40,41) and promoting beige adipocyte biogen-
esis in WAT (42), likely through rostral raphe pallidus
(rRPa) neurons (43). In addition, we found that capsi-
noids increased b2-AR expression in the inguinal WAT.
On the other hand, cold exposure acts on distinct neu-
ronal circuits from capsinoids to activate thermogenesis. In
response to cold exposure, thermal sensory receptors trans-
mit signals to second-order thermal sensory neurons in the
dorsal horn. These neurons activate the signal to the pre-
optic area where gabanergic neurons control the outputs to
the neurons at the dorsomedial nucleus of the hypothala-
mus and subsequently in the rRPa nucleus (44). Hence, it is
conceivable that capsinoids and mild cold exposure stim-
ulate the respective neuronal circuits independently such
that a combination of the two independent stimuli pro-
motes an additive thermogenic response more potently
than single stimulation alone.
Within the inguinal WAT of mice treated with capsinoids,
we found that the PRDM16 protein level was robustly
increased without affecting its mRNA expression. PRDM16
functions as a dominant transcriptional regulator of brown
and beige adipocyte development (33–37). A requirement of
PRDM16 for beige adipocyte development has been dem-
onstrated by studies in which adipose-specific depletion of
PRDM16 significantly impaired beige adipocyte biogenesis
in response to cold exposure or to long-term treatment
with PPARg agonists (27,33). We have shown that PPARg
agonists, such as rosiglitazone, promote beige adipocyte
(saline) or the b2-AR agonist (formoterol) at a dose of 1 mg/kg/day or b3-AR agonist (CL316234) at a dose of 1 mg/kg/day under ambient
temperature for 1 week (n = 6). *P < 0.05, ***P < 0.001. F: UCP1 protein expression was analyzed by Western blotting in the inguinal WAT
of mice shown in panel E. b-Actin was used as a loading control. G: Hematoxylin and eosin staining of the inguinal WAT of mice shown in
panel E. Scale bar = 100 mm. Note that b2-AR agonist (formoterol) treatment led to a striking increase in the number of multilocular ad-
ipocytes in the inguinal WAT. N.S., not significant.
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Figure 5—Capsinoids (CSNs) stimulate a stabilization of the PRDM16 protein through the b2-AR pathway. A: Endogenous PRDM16
protein and relative mRNA expression of Prdm16 in the inguinal WAT of mice kept under ambient temperature (RT) or 17°C (n = 6).
Mice were fed an HFD supplemented with 0.3% CSNs (+) or vehicle (CSNs [2]) for 8 weeks. b-Actin was used as a loading control for
Western blotting. The Prdm16mRNA expression data are mean6 SEM. B: Endogenous PRDM16 protein and relative mRNA expression of
Prdm16 in the inguinal WAT of WT mice and b-less mice under 17°C (n = 6). Mice were fed an HFD supplemented with 0.3% CSNs (+) or
vehicle (CSNs [2]) for 4 weeks. b-Actin was used as a loading control for Western blotting. C: PRDM16 protein expression was analyzed by
Western blotting in the inguinal WAT of mice injected with vehicle (saline) or b2-AR agonist (formoterol) at a dose of 1 mg/kg/day for 1 week
(n = 5). b-Actin was used as a loading control. D: Protein expression of PRDM16 and UCP1 was analyzed by Western blotting in primary
inguinal WAT–derived adipocytes. The cells were cultured in the absence or presence of b2-AR agonist (formoterol) or b3-AR agonist
(CL316243) at doses of 0.01 and 1 mmol/L throughout adipocyte differentiation (n = 3). b-Actin was used as a loading control. Relative
Prdm16 mRNA expression in these cells is also shown. E: Cycloheximide (CHX) chase experiment in primary inguinal WAT–derived
adipocytes. Endogenous PRDM16 protein expression was analyzed by Western blotting. Differentiated adipocytes were treated with
vehicle or b2-AR agonist (formoterol) at a dose of 1 mmol/L in the presence of CHX for 1, 8, 16, and 24 h. b-Actin was used as a loading
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differentiation by powerfully extending the protein half-
life of PRDM16 through inhibiting E3 ligase–mediated
ubiquitination (27). In addition, rosiglitazone deacetylates
PPARg on Lys268 and Lys293 by Sirt1, leading to an en-
hanced complex formation between PRDM16 and PPARg
(45). In the current study, we found that capsinoids treat-
ment induces the protein stabilization of PRDM16 through
b2-AR signaling. It is known that an activation of b2-AR
leads to phosphorylation of protein kinase A, p38 mitogen–
activated protein kinase, extracellular signal–regulated
kinase, and AMPK (46–48). It is possible that PRDM16
protein is phosphorylated in response to an activation of
b2-AR signaling, leading to an increase in PRDM16 protein
stability. Future studies are warranted to better understand
the molecular mechanisms by which the b2-AR signal ex-
tends the half-life of PRDM16 protein.
Previous studies have shown that obese propensity in
response to an HFD is highly strain dependent (49). In
addition, browning capacity in the subcutaneous WAT de-
pot is highly variable among mouse strains (50–52). Al-
though we found that antiobesity and browning effects by
mild cold exposure and capsinoids were more potent in
the C57BL/6J background than in the mixed background,
these effects were consistently observed in both strains.
On the other hand, in previous studies, the effects of
capsinoids on hepatic steatosis were observed even under
ambient temperature. For instance, treatment with cap-
sinoids alone was sufficient to reduce hepatic lipid and TG
content by 44% and 29%, respectively. The current study
also found that capsinoids treatment increased the ex-
pression of genes involved in hepatic fatty acid oxidation,
such as Hsl, Atgl, and Aco, under ambient temperature
(Supplementary Fig. 11). This increase in hepatic fatty
acid oxidation may contribute to the improvement in lipid
metabolism in the liver (e.g., reduced hepatic lipid and TG
content) by capsinoids treatment. Relative contribution of
liver versus adipose tissue to the improvement of sys-
temic glucose homeostasis remains to be determined.
The biological significance of beige fat in whole-body
metabolism has been a topic of discussion because total
expression level of UCP1 protein in beige fat is substantially
lower than that found in interscapular BAT depots, even
though beige adipocytes are functionally thermogenic (Sup-
plementary Fig. 6) (53). In the current study, we found that
control. Regression analysis of PRDM16 protein stability is also shown. F: Relative mRNA expression of Prdm16 and Ucp1 was measured
by qRT-PCR in primary inguinal WAT–derived adipocytes infected with sh-scr or sh-PRDM16 (n = 3). The adipocytes were treated with
vehicle (control) and b2-AR agonist (formoterol) at a dose of 1 mmol/L throughout adipocyte differentiation. **P < 0.01, ***P < 0.001.
G: PRDM16 and UCP1 protein expression was analyzed by Western blotting in the primary inguinal WAT–derived adipocytes shown in
panel F. b-Actin was used as a loading control. Cont, control; N.S., not significant; T1/2, half-life.
Figure 6—Proposed mechanisms by which capsinoids and mild cold temperature promote beige adipocyte biogenesis and energy
expenditure. Capsinoids bind to TRPV1 in gut. The signal is transmitted to the CNS through vagal nerves that project into the VMH.
The signal is subsequently transmitted to subcutaneous WAT depots through the b2-AR in inguinal WAT. Capsinoids increase the
expression of b2-AR. However, cold is sensed by skin and transmitted to the somatosensory nerves through second-order thermal sensory
neurons in the dorsal horn (DH). These neurons activate the signal to the preoptic area (POA) where gabanergic neurons control the outputs to
the neurons at the dorsomedial nucleus of the hypothalamus (DMH) and subsequently in the rRPa nucleus. These stimuli synergistically
promote beige adipocyte biogenesis through stabilizing PRDM16 protein in inguinal WAT, leading to an increase in whole-body energy
expenditure and a decrease in fasting insulin levels and hepatic TG content. DRG, dorsal root ganglion; NG, nodose ganglion.
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an increased beige fat mass by capsinoids and mild cold
exposure was tightly associated with an increase in whole-
body energy expenditure. Of note, the increase in energy
expenditure leads to a robust reduction in body weight
gain while on an HFD, indicating that beige fat significantly
contributes to the regulation of whole-body energy expen-
diture. This is consistent with several genetic mouse models
in which selective modulation of beige fat mass is sufficient
to alter whole-body metabolism. For example, transgenic
expression of PRDM16 driven by the Fabp4 gene promoter
preferentially stimulates the formation of beige adipocytes
in the subcutaneous WAT depots without major changes in
the interscapular BAT depots. The Fabp4-PRDM16 trans-
genic mice exhibit increased whole-body energy expendi-
ture and reduced body weight gain while on an HFD
(54). Conversely, adipose-selective genetic deletion of
Prdm16 or its cofactor EHMT1 by using Adiponectin-Cre
mice selectively attenuates beige adipocyte development
and reduces whole-body energy expenditure (33,55). Also
of note, beige fat plays a major role in systemic glucose
and lipid homeostasis. Because brown and beige adipo-
cytes possess high oxidative phosphorylation capacity,
they function as a metabolic sink for glucose and fatty
acids. Indeed, we found that liver TG level was strikingly
lower in mice treated with capsinoids under mild cold in
parallel with an increased beige fat mass. Conversely, a
developmental defect in brown/beige adipocytes is suffi-
cient to cause hepatic steatosis and insulin resistance in
mice (33,55). Hence, the therapeutic benefit of increased
beige fat mass not only is limited to antiobesity effects
but also can include improvements in hepatic steatosis
and insulin resistance.
In summary, the current study found a previously
unappreciated molecular circuit that preferentially pro-
motes beige adipocyte biogenesis in vivo. Given the relevance
of this cell type in adult humans, this study also illuminates
a plausible approach to increase whole-body energy expen-
diture and to improve lipid and glucose homeostasis by
combining dietary components and environmental cues. It
has been reported that chronic supplementation of capsi-
noids at a dose of 9 mg/day for 6 weeks was able to increase
cold-stimulated whole-body energy expenditure even in adult
humans who lacked detectable active BAT depots before
the treatment (20). Because 1 g dry weight of CH-19 Sweet
contains ;5 mg of capsinoids (56), we speculate that sup-
plementary intake would be a realistic approach to achieve
the levels of capsinoids that can activate BAT thermogenesis.
Future studies aim to establish practical approaches to acti-
vate BAT thermogenesis by capsinoids supplementation and
mild cold with no deleterious effects.
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